- Home
- ENPH vs TERN Comparison
ENPH vs TERN Comparison
Compare ENPH & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ENPH | TERN |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.8B |
| IPO Year | 2011 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ENPH | TERN |
|---|---|---|
| Price | $36.41 | $52.97 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 23 | 12 |
| Target Price | $41.30 | ★ $45.22 |
| AVG Volume (30 Days) | ★ 6.5M | 4.2M |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.00 | 8.04 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,472,985,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.81 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.72 | N/A |
| 52 Week Low | $25.78 | $2.82 |
| 52 Week High | $54.43 | $53.19 |
Technical Indicators
Market Signals| Indicator | ENPH | TERN |
|---|---|---|
| Relative Strength Index (RSI) | 53.96 | 74.51 |
| Support Level | $34.66 | $52.42 |
| Resistance Level | $38.43 | $53.19 |
| Average True Range (ATR) | 2.25 | 0.07 |
| MACD | 0.58 | -0.31 |
| Stochastic Oscillator | 89.02 | 97.30 |
Price Performance
Historical ComparisonAbout ENPH Enphase Energy Inc.
Enphase Energy is a global energy technology company. It delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Enphase derives a majority of revenue from the United States.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.